Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26641
The first proteins should reach those markets in 2009 to treat diseases such as cancer and multiple sclerosis. The deal means Tunisia will be home to the first manufacturing facility for therapeutic proteins in that part of the world.
IPSCIO Record ID: 26640
Â·Recombinant Human Interferon alpha-2a (rHulFN-a 2a) and alpha-2b (rHulFN-a 2b)
Â·Recombinant Human granulocyte colony stimulating factor (rHuG-CSF);
Â·Recombinant Human granulocyte macrophage colony stimulating factor (rHuGM-CSF);
The Company has acquired license to patented technologies related to the production of therapeutic proteins, alpha and beta interferon, Interleukin 2, EPO (erythropoietin) and human growth factors (rHuG-CSF and rHuGM-CSF).
IPSCIO Record ID: 25837
NX-1207 is an office-based pro-apoptotic protein injectable for BPH and for low grade localized prostate cancer. The drug mechanism of action is to lead to programmed natural cell death (apoptosis) selectively in prostate glands when injected intraprostatically by the transrectal route.